Dr. Moskowitz on the ALCANZA Trial in CTCL
2 Views
administrator
08/09/23
Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).
-
Category
Show more
Facebook Comments
No comments found